Arkolith/Insider Trading/VRCA/Form 4

Manning Paul B

Director, 10% OwnerVerrica Pharmaceuticals Inc. (VRCA) · full profile →Form 4 · filed Nov 25, 2025
Net Buying
Open-Market Buys
$17.5M
Open-Market Sells
$0
Net Open-Market Flow
$17.5M
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 25, 2025Buy(P)1.4M$4.24$5.8M4.0M
Nov 25, 2025Buy(P)2.8M$4.24$11.7M3.3M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 25, 2025Buy(P)344K——344K
Nov 25, 2025Buy(P)688K——688K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001494695-25-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML